Expert Ratings for Moderna Within the last quarter, Moderna (NASDAQ:MRNA) has observed the following analyst ratings: Benzinga · Jun 7, 2022
The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study Here's a roundup of top developments in the biotech space over the last 24 hours: Benzinga · Jun 7, 2022
Moderna Commences Late-stage Study of Flu Vaccine Candidate Moderna, Inc. (NASDAQ: MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza. Benzinga · Jun 7, 2022
Kids under 5 should soon have access to COVID vaccines, but many parents are likely to say, I don’t feel comfortable' PHILADELPHIA — Zoli’s parents plan to get their 4-year-old son vaccinated against COVID-19 as soon as shots for young children could finally become available later this month. The Philadelphia Inquirer · Jun 6, 2022
We still need a vaccine patent waiver, but not the one on offer at the World Trade Organization meeting In mid-June, the World Trade Organization (WTO) will meet to finish negotiations to waive certain sections of the agreement on Trade Related Intellectual Property Rights (TRIPS). However, it is not the TRIPS waiver originally proposed 18 months ago by member states South Africa and India, which would have allowed countries… The Conversation · Jun 5, 2022
NOT REAL NEWS: A look at what didn't happen this week Social media users shared a range of false claims this week The Independent UK · Jun 3, 2022
Covid vaccines for the under-fives - what parents need to know Children under five represent the only age group yet to have a vaccine approved for use Wales Online · Jun 2, 2022
Pfizer Seeks FDA Approval For Three Covid Vaccine Doses For Children Below Five Partners Pfizer, Inc (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) urged the FDA to authorize three vaccine doses for children below five, the Wall Street Journal reports. The companies previously asserted that three doses of the shot were 80% effective at preventing symptomatic Covid-19 with robust immune response in children between six months to five years. After mixed results… Benzinga · Jun 2, 2022
Japan study shows women more likely to get skin rash from Moderna shot A study in Japan found that women were significantly more likely than men to develop rash-like side effects after a first dose of Moderna Inc's COVID-19 vaccine. Reuters · Jun 2, 2022
Check Out What Whales Are Doing With MRNA Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Benzinga · Jun 1, 2022
COVID vaccines for children under five: what parents need to know Pfizer’s COVID-19 vaccine became available for children aged five to 11 in the UK in April 2022. Those aged 12 and up had already been eligible since 2021. The Conversation · Jun 1, 2022
Planning a holiday? What’s the COVID situation in Bali, Fiji, NZ and the UK? Here are a few general tips for a safer and enjoyable holiday, and a quick look at the COVID situation in four popular holiday destinations. The New Daily · May 27, 2022
CanSino's Covid Vaccine Gets WHO Nod. But Is It Too Little, Too Late? Key Takeaways: CanSino’s Covid-19 vaccine Convidecia will be admitted to the global Covax program following its approval by the WHO The approval could have limited benefits for the company as the pandemic fades and other products are widely available By Jony Ho Benzinga · May 26, 2022
How important is the COVID-19 booster shot for 5-to-11-year-olds? 5 questions answered COVID-19 case numbers are rising again in the U.S. – including among children. In mid-May 2022, the Food and Drug Administration authorized a booster shot of the COVID-19 vaccine for U.S. children ages 5 to 11, and the Centers for Disease Control and Prevention followed by recommending a booster shot… The Conversation · May 26, 2022
Benzinga · May 25, 2022 Time 100 Most Influential List Includes 10 Connected To Public Companies Such As Tim Cook, Andy Jassy And Joe Rogan The annual Time 100 Most Influential People list for 2022 contains names such as U.S. President Joe Biden, Ukrainian President Volodymyr Zelenskyy and Chinese President Xi Jinping. The list also has several CEOs and names connected to public companies.
Asharq Al-Awsat · May 24, 2022 Moderna Testing Potential Monkeypox Vaccines Moderna Inc is testing potential vaccines against monkeypox in pre-clinical trials as the disease spreads in the United States and Europe. The World Health Organization said on Tuesday there have been 131 confirmed monkeypox cases and 106 further suspected cases since the first was reported on May 7 outside the…
Benzinga · May 24, 2022 Peering Into Moderna's Recent Short Interest Moderna's (NASDAQ:MRNA) short percent of float has fallen 3.7% since its last report. The company recently reported that it has 15.43 million shares sold short, which is 4.43% of all regular shares that are available for trading.
Wales Online · May 24, 2022 What happened to the AstraZeneca vaccine? How blood clot scares tarnished its reputation While the AZ./Oxford vaccine has all but vanished from richer countries, it has continued to be rolled out elsewhere
The Independent UK · May 24, 2022 China's bet on homegrown mRNA vaccines holds back nation China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19
Benzinga · May 23, 2022 Here's How Much You Would Have Made Owning Moderna Stock In The Last 5 Years Moderna (NASDAQ:MRNA) has outperformed the market over the past 5 years by 102.55% on an annualized basis producing an average annual return of 112.95%. Currently, Moderna has a market capitalization of $54.60 billion.
The Independent UK · May 23, 2022 What's next for COVID-19 vaccines for youngest US children Parents hoping to get their youngest children vaccinated against COVID-19 have some encouraging news
Benzinga · May 23, 2022 Looking At Moderna's Recent Whale Trades Someone with a lot of money to spend has taken a bullish stance on Moderna (NASDAQ:MRNA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.
The Independent UK · May 23, 2022 Pfizer says 3 COVID shots protect children under 5 Pfizer says three small doses of its COVID-19 vaccine protect kids under 5 and that it plans to give the data to U.S. regulators later this week
Benzinga · May 19, 2022 Moderna Soars Following FDA Comments On COVID-19 Vaccine For Kids Under 5: What's Next? Moderna, Inc (NASDAQ: MRNA) was spiking higher on Thursday, holding up better than the general markets, which saw the S&P 500 rally over 1% off the open before giving it all back.
Benzinga · May 18, 2022 The Daily Biotech Pulse: Pfizer/BioNTech's COVID-19 Booster For Kids, Moderna Starts First African Trial Of mRNA HIV Vaccine, Tonix Extends COVID-19 Antiviral Research Pact Here's a roundup of top developments in the biotech space over the last 24 hours.